WHO ICTRP trial
Optimizing therapy with n=1-studies: negating the 'nocebo' effect in…
CTIS2023-507489-20-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-507489-20-00 |
|---|---|
| Public title | Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance |
| Scientific title | N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE) |
| Primary sponsor | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): Yes |
| Countries | Netherlands |
| Conditions | Statin-intolerance, High cardiovascular risk (previous cardiovascular disease or familial hypercholesterolemia);Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] |
| Interventions | Product Name: Placebo of rosuvastatin 10mg (tablet) as produced by Apotheek A15, Product Code:N/A, Pharmaceutical Form: N/A, Other descriptive name: N/A , Strength: , Pharmaceutical form of the placebo: N/A , Product Name: Rosuvastatin… |
| Registration date | Oct 6, 2024 |
| Target size | 249 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: